Slingshot members are tracking this event:
Celldex (CLDX) Presents Phase 2 Data Evaluating Glembatumumab Vedotin in Metastatic Melanoma
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Oct 09, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Glembatumumab Vedotin, Metastatic Melanoma, Gpnmb